AbbVie's R&D expenditures as revenue share 2012-2019

This statistic illustrates the expenditure of AbbVie on research and development as a percentage of revenue from 2012 to 2019. In 2019, AbbVie spent some 19 percent of its revenue on research and development. Abbot was a U.S.-based global pharmaceutical and healthcare products company, headquartered in Chicago, Illinois. In January 2013, Abbott was separated into two companies: Abbott Laboratories and AbbVie. Abbott Laboratories is now specialized on medical products, while AbbVie is responsible for research-based pharmaceuticals.

AbbVie's research and development spending as a share of revenue from 2012 to 2019

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in

Release date




Survey time period

2012 to 2019

Supplementary notes

This statistic was assembled from several of Abbvie's annual reports.
* Research and development expenses in 2018 increased from 2017 principally due to a $5.1 billion intangible asset impairment charge related to IPR&D acquired as part of the 2016 Stemcentrx acquisition following the decision to stop enrollment in the TAHOE trial.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.